Recently Added Drugs
1. Adempas patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12503469 | BAYER | NA |
Feb, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 08, 2020 |
| Orphan Drug Exclusivity(ODE-53) | Oct 08, 2020 |
Drugs and Companies using RIOCIGUAT ingredient
NCE-1 date: 08 October, 2017
Market Authorisation Date: 08 October, 2013
Treatment: Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening
Dosage: TABLET
How can I launch a generic of ADEMPAS before its drug patent expiration?
More Information on Dosage
ADEMPAS family patents
2. Akeega patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11986470 | JANSSEN | Methods Of Treating Prostate Cancer |
Jul, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 11, 2026 |
| New Indication(I-980) | Dec 12, 2028 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: A method for treating metastatic castration-sensitive prostate cancer (mcspc), wherein the cancer is associated with a deleterious brca2-mutation
Dosage: TABLET
More Information on Dosage
AKEEGA family patents
3. Aqvesme patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE49582 | AGIOS | Therapeutic compounds and compositions |
Feb, 2031
(4 years from now) | |
| US11254652 | AGIOS | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Nov, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10632114 | AGIOS | Pyruvate kinase activators for use in therapy |
May, 2032
(6 years from now) | |
| US9682080 | AGIOS | Pyruvate kinase activators for use in therapy |
May, 2032
(6 years from now) | |
| US9193701 | AGIOS | Pyruvate kinase activators for use in therapy |
Oct, 2032
(6 years from now) | |
| US11878049 | AGIOS | Mitapivat therapy and modulators of cytochrome P450 |
Jul, 2041
(15 years from now) | |
Drugs and Companies using MITAPIVAT SULFATE ingredient
NCE-1 date: 17 February, 2026
Market Authorisation Date: 23 December, 2025
Treatment: Method of using a pyruvate kinase activator for treating anemia in adults with alpha or beta thalassemia; Method of using a pyruvate kinase activator for the treatment of anemia in adults with alpha o...
Dosage: TABLET
More Information on Dosage
AQVESME family patents
4. Avmapki Fakzynja Co-pack (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12509450 | VERASTEM | Solid Forms Of A Dual Raf/Mek Inhibitor |
Dec, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2030 |
Drugs and Companies using AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE ingredient
NCE-1 date: 08 May, 2029
Market Authorisation Date: 08 May, 2025
Treatment: NA
Dosage: CAPSULE, TABLET
More Information on Dosage
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) family patents
5. Bylvay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12508234 | IPSEN | Pharmaceutical Formulation Of Odevixibat |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-918) | Jun 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity(ODE-363) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-436) | Jun 13, 2030 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 20 July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)
Dosage: CAPSULE, PELLETS; CAPSULE
More Information on Dosage
BYLVAY family patents
6. Cardamyst patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10010523 | MILESTONE | Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof |
Jun, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10010522 | MILESTONE | Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof |
Jun, 2028
(2 years from now) | |
| US9227918 | MILESTONE | Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof |
Jun, 2028
(2 years from now) | |
| US9463179 | MILESTONE | Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof |
Jun, 2028
(2 years from now) | |
| US10117848 | MILESTONE | Highly Water-Soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker And Uses Thereof |
Apr, 2036
(10 years from now) | |
| US12257224 | MILESTONE | Methods Of Administration For Highly Water-Soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker |
Jul, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2030 |
Drugs and Companies using ETRIPAMIL ingredient
NCE-1 date: 12 December, 2029
Market Authorisation Date: 12 December, 2025
Treatment: Treatment of paroxysmal supraventricular tachycardia; Treatment of a cardiac arrhythmia
Dosage: SPRAY
More Information on Dosage
CARDAMYST family patents
7. Cosela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12527798 | PHARMACOSMOS | NA |
Dec, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 12 February, 2025
Market Authorisation Date: 12 February, 2021
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen that includes an immune checkpoint inhi...
Dosage: POWDER
How can I launch a generic of COSELA before its drug patent expiration?
More Information on Dosage
COSELA family patents
8. Daybue patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12492167 | ACADIA | NA |
Jul, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2028 |
| Orphan Drug Exclusivity(ODE-425) | Mar 10, 2030 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 11 March, 2027
Market Authorisation Date: 10 March, 2023
Treatment: Treatment of rett syndrome or a symptom thereof
Dosage: SOLUTION
More Information on Dosage
DAYBUE family patents
9. Daybue Stix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11370755 | ACADIA | Compositions of trofinetide |
Aug, 2040
(14 years from now) | |
| US11827600 | ACADIA | Crystalline forms of trofinetide |
Jul, 2042
(16 years from now) | |
| US12492167 | ACADIA | NA |
Jul, 2042
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9212204 | ACADIA | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid |
Jan, 2032
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2028 |
| ODE*(ODE*) | Mar 10, 2030 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 11 March, 2027
Market Authorisation Date: 11 December, 2025
Treatment: Treatment of rett syndrome or a symptom thereof
Dosage: FOR SOLUTION
More Information on Dosage
DAYBUE STIX family patents
10. Epinephrine patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12539283 | FRESENIUS KABI | NA |
Jan, 2045
(18 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 13 March, 2025
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of EPINEPHRINE before its drug patent expiration?
More Information on Dosage
EPINEPHRINE family patents
11. Firmagon patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12514898 | FERRING | Methods Of Treating Prostate Cancer With Gnrh Antagonist |
Feb, 2029
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 24, 2013 |
Drugs and Companies using DEGARELIX ACETATE ingredient
NCE-1 date: 24 December, 2012
Market Authorisation Date: 24 December, 2008
Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect
Dosage: POWDER
How can I launch a generic of FIRMAGON before its drug patent expiration?
More Information on Dosage
FIRMAGON family patents
12. Flyrcado patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12527884 | GE HEALTHCARE | NA |
May, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2029 |
Drugs and Companies using FLURPIRIDAZ F-18 ingredient
NCE-1 date: 27 September, 2028
Market Authorisation Date: 27 September, 2024
Treatment: Method of positron emission tomography (pet) for cardiac diseases
Dosage: SOLUTION
More Information on Dosage
FLYRCADO family patents
13. Gloperba patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12514819 | SCILEX | Colchicine Drug-To-Drug Interactions |
Nov, 2036
(10 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 30 January, 2019
Treatment: A method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution
Dosage: SOLUTION
How can I launch a generic of GLOPERBA before its drug patent expiration?
More Information on Dosage
GLOPERBA family patents
14. Ibsrela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12539299 | ARDELYX | NA |
Nov, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
IBSRELA family patents
15. Jardiance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12527810 | BOEHRINGER INGELHEIM | NA |
Apr, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | Jun 26, 2018 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Indication(I-869) | Aug 18, 2024 |
| M(M-82) | Feb 24, 2025 |
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-922) | Sep 21, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 01 August, 2014
Treatment: Use of empagliflozin as an adjunct to diet and exercise to improve glycemic control in pediatric patients aged 10 years to 17 years with type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of JARDIANCE before its drug patent expiration?
More Information on Dosage
JARDIANCE family patents
16. Jevtana Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10583110 (Pediatric) | SANOFI | Antitumoral Use Of Cabazitaxel |
Apr, 2031
(5 years from now) | |
|
US10716777 (Pediatric) | SANOFI | Antitumoral Use Of Cabazitaxel |
Apr, 2031
(5 years from now) | |
|
US12453712 (Pediatric) | SANOFI | Antitumoral Use Of Cabazitaxel |
Apr, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2015 |
| M(M-201) | May 17, 2020 |
| M(M-209) | Sep 14, 2020 |
| Pediatric Exclusivity(PED) | Nov 17, 2020 |
| M(M-128) | Dec 18, 2023 |
Drugs and Companies using CABAZITAXEL ingredient
NCE-1 date: 18 November, 2019
Market Authorisation Date: 17 June, 2010
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of JEVTANA KIT before its drug patent expiration?
More Information on Dosage
JEVTANA KIT family patents
17. Kimyrsa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12514899 | MELINTA | Methods Of Treatment Using Single Doses Of Oritavancin |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
| New Product(NP) | Mar 12, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 12 March, 2021
Treatment: Treatment of acute bacterial skin and skin structure infections caused by streptococcus dysgalactiae with a single dose of 1200mg oritavancin or its single dose equivalent
Dosage: POWDER
More Information on Dosage
KIMYRSA family patents
18. Kisqali patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12544379 | NOVARTIS | NA |
Aug, 2034
(8 years from now) | |
| US12544380 | NOVARTIS | NA |
Aug, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-783) | Jul 18, 2021 |
| New Indication(I-784) | Jul 18, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-950) | Sep 17, 2027 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy, for the treatment of adult patients with hr-positive, her2-negative advanced o...
Dosage: TABLET
How can I launch a generic of KISQALI before its drug patent expiration?
More Information on Dosage
KISQALI family patents
19. Kisqali Femara Co-pack (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12544380 | NOVARTIS | NA |
Aug, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-951) | Sep 17, 2027 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: Adjuvant treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative stage ii and iii early breast cancer at high risk of recurrence
Dosage: TABLET
How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before its drug patent expiration?
More Information on Dosage
KISQALI FEMARA CO-PACK (COPACKAGED) family patents
20. Komzifti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12521396 | KURA | NA |
Jul, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2030 |
Drugs and Companies using ZIFTOMENIB ingredient
NCE-1 date: 13 November, 2029
Market Authorisation Date: 13 November, 2025
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
KOMZIFTI family patents
21. Lynkuet patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12533358 | BAYER | NA |
May, 2045
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 24, 2030 |
Drugs and Companies using ELINZANETANT ingredient
NCE-1 date: 24 October, 2029
Market Authorisation Date: 24 October, 2025
Treatment: Treatment of moderate to severe vasomotor symptoms due to menopause by administering 60 mg (one capsule) of lynkuet orally once daily at bedtime concomitantly with a moderate cyp3a4 inhibitor
Dosage: CAPSULE
More Information on Dosage
LYNKUET family patents
22. Mavenclad patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12533408 | EMD SERONO | NA |
Sep, 2041
(15 years from now) | |
| US12539329 | EMD SERONO | NA |
Sep, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 29, 2022 |
Drugs and Companies using CLADRIBINE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Treatment of relapsing forms of multiple sclerosis in adults by administering 2 yearly treatment courses wherein patients who are seropositive to vzv are vaccinated with zoster vaccine recombinant, ad...
Dosage: TABLET
How can I launch a generic of MAVENCLAD before its drug patent expiration?
More Information on Dosage
MAVENCLAD family patents
23. Mounjaro patent expiration
MOUNJARO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343382 | ELI LILLY | Methods Of Using A Gip/Glp1 Co-Agonist For Therapy |
Jul, 2039
(13 years from now) | |
| US12295987 | ELI LILLY | Method of using a GIP/GLP1 co-agonist for diabetes |
Dec, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Method of improving glycemic control by administering a once weekly escalation dose of 2.5 mg, 7.5 mg, or 12.5 mg of tirzepatide for at least 2 weeks and a once-weekly maintenance dose of 5 mg, 10 mg,...
Dosage: SOLUTION
More Information on Dosage
MOUNJARO family patents
24. Mounjaro Kwikpen patent expiration
MOUNJARO KWIKPEN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343382 | ELI LILLY | Methods Of Using A Gip/Glp1 Co-Agonist For Therapy |
Jul, 2039
(13 years from now) | |
| US12295987 | ELI LILLY | Method of using a GIP/GLP1 co-agonist for diabetes |
Dec, 2041
(15 years from now) | |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Method of improving glycemic control by subcutaneously administering a first once-weekly dose of 2.5 mg tirzepatide for 4 weeks, increasing the once-weekly dose by increments of 2.5 mg to a once-weekl...
Dosage: SOLUTION
More Information on Dosage
MOUNJARO KWIKPEN family patents
25. Myqorzo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10836755 | CYTOKINETICS | Cardiac Sarcomere Inhibitors |
Jan, 2039
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12370179 | CYTOKINETICS | NA |
Jul, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2030 |
Drugs and Companies using AFICAMTEN ingredient
NCE-1 date: 19 December, 2029
Market Authorisation Date: 19 December, 2025
Treatment: Treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (ohcm) to improve functional capacity and symptoms
Dosage: TABLET
More Information on Dosage
MYQORZO family patents
26. Nereus patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10772880 | VANDA | Method Of Treatment With Tradipitant |
Mar, 2036
(10 years from now) | |
| US10821099 | VANDA | Use Of Tradipitant In Motion Sickness |
Mar, 2036
(10 years from now) | |
| US11324735 | VANDA | Method Of Treatment With Tradipitant |
Mar, 2036
(10 years from now) | |
| US12318375 | VANDA | Method Of Treatment With Tradipitant |
Aug, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 30, 2030 |
Drugs and Companies using TRADIPITANT ingredient
NCE-1 date: 30 December, 2029
Market Authorisation Date: 30 December, 2025
Treatment: Prevention of vomiting induced by motion in adults by administering tradipitant
Dosage: CAPSULE
More Information on Dosage
NEREUS family patents
27. Norepinephrine Bitartrate In 0.9% Sodium Chloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE49422 | INFORLIFE | Process for producing a stable low concentration, injectable solution of noradrenaline |
Feb, 2035
(8 years from now) | |
| USRE49443 | INFORLIFE | Process for producing a stable low concentration, injectable solution of noradrenaline |
Feb, 2035
(8 years from now) | |
| US10888534 | INFORLIFE | Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags |
Apr, 2039
(13 years from now) | |
Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient
Market Authorisation Date: 15 September, 2022
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE before its drug patent expiration?
More Information on Dosage
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents
28. Nuzolvence patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8658641 | ENTASIS | Fused, Spirocyclic Heteroaromatic Compounds For The Treatment Of Bacterial Infections |
Jun, 2030
(4 years from now) | |
| US8889671 | ENTASIS | Compounds And Methods For Treating Bacterial Infections |
Jan, 2034
(7 years from now) | |
| US9187495 | ENTASIS | Compounds And Methods For Treating Bacterial Infections |
Jan, 2034
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9040528 | ENTASIS | Chemical Compounds 542 |
Oct, 2029
(3 years from now) | |
| US9540394 | ENTASIS | Compounds And Methods For Treating Bacterial Infections |
Jan, 2034
(7 years from now) | |
| US9839641 | ENTASIS | Compounds And Methods For Treating Bacterial Infections |
Jan, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Dec 12, 2035 |
Drugs and Companies using ZOLIFLODACIN ingredient
NCE-1 date: 12 December, 2029
Market Authorisation Date: 12 December, 2025
Treatment: Treatment of uncomplicated urogenital gonorrhea due to neisseria gonorrhoeae
Dosage: FOR SUSPENSION
More Information on Dosage
NUZOLVENCE family patents
29. Orbactiv patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12514899 | MELINTA | Methods Of Treatment Using Single Doses Of Oritavancin |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 06 August, 2014
Treatment: Treatment of acute bacterial skin and skin structure infections caused by streptococcus dysgalactiae with a single dose of 1200mg oritavancin or its single dose equivalent
Dosage: POWDER
More Information on Dosage
ORBACTIV family patents
30. Potassium Chloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12539314 | GENUS | NA |
Mar, 2039
(13 years from now) | |
Drugs and Companies using POTASSIUM CHLORIDE ingredient
Market Authorisation Date: 25 November, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
POTASSIUM CHLORIDE family patents
31. Radicava Ors patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12527769 | KK BCJ 94 | NA |
Nov, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 12, 2025 |
| Orphan Drug Exclusivity(ODE-144) | May 12, 2029 |
Drugs and Companies using EDARAVONE ingredient
Market Authorisation Date: 12 May, 2022
Treatment: Treatment of amyotrophic lateral sclerosis by administering a liquid edaravone composition relative to the timing and type of food consumption
Dosage: SUSPENSION
How can I launch a generic of RADICAVA ORS before its drug patent expiration?
More Information on Dosage
RADICAVA ORS family patents
32. Rezenopy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12514854 | SCIENTURE | Drug Products For Intranasal Administration And Uses Thereof |
Feb, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 19, 2027 |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 April, 2024
Treatment: Treatment of opioid overdose
Dosage: SPRAY
More Information on Dosage
REZENOPY family patents
33. Romvimza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12528787 | DECIPHERA | NA |
Dec, 2044
(18 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12509443 | DECIPHERA | Csf-1R Inhibitors And Methods Of Use Thereof |
Apr, 2045
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2030 |
Drugs and Companies using VIMSELTINIB ingredient
NCE-1 date: 14 February, 2029
Market Authorisation Date: 14 February, 2025
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
ROMVIMZA family patents
34. Rybelsus patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12514822 | NOVO NORDISK | Oral Dosing Of Glp-1 Compounds |
May, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
| New Indication(I-976) | Oct 17, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 09 December, 2024
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of RYBELSUS before its drug patent expiration?
More Information on Dosage
RYBELSUS family patents
35. Sotyktu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12521390 | BRISTOL | Dosage Forms For Tyk2 Inhibitors |
Feb, 2043
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 09, 2027 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: 09 September, 2026
Market Authorisation Date: 09 September, 2022
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Dosage: TABLET
More Information on Dosage
SOTYKTU family patents
36. Syfovre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12528836 | APELLIS | NA |
Oct, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of 15 mg pegcetacoplan
Dosage: SOLUTION
More Information on Dosage
SYFOVRE family patents
37. Tryngolza (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12509684 | IONIS | Compositions And Methods For Modulating Apolipoprotein C-Iii Expression |
May, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-515) | Dec 19, 2031 |
Drugs and Companies using OLEZARSEN SODIUM ingredient
Market Authorisation Date: 19 December, 2024
Treatment: Use in reducing triglycerides in adults with familial chylomicronemia syndrome (fcs)
Dosage: SOLUTION
More Information on Dosage
TRYNGOLZA (AUTOINJECTOR) family patents
38. Uptravi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7205302 (Pediatric) | ACTELION | Heterocyclic Compound Derivatives And Medicines |
Apr, 2027
(1 year, 1 month from now) | |
|
US9173881 (Pediatric) | ACTELION | Therapeutic Compositions Containing Macitentan |
Feb, 2030
(3 years from now) | |
|
US9284280 (Pediatric) | ACTELION | Use Of Form-I Crystal Of 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide |
Dec, 2030
(4 years from now) | |
|
US8791122 (Pediatric) | ACTELION | Form-I Crystal Of 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide And Method For Producing The Same |
Feb, 2031
(4 years from now) | |
|
US10821108 (Pediatric) | ACTELION | Pharmaceutical Composition Containing 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide |
Jun, 2037
(11 years from now) | |
|
US10828298 (Pediatric) | ACTELION | Pharmaceutical Composition Containing 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy]-N-(Methylsulfonyl)Acetamide |
Jun, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
| Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
Drugs and Companies using SELEXIPAG ingredient
NCE-1 date: 22 December, 2019
Market Authorisation Date: 21 December, 2015
Treatment: NA
Dosage: TABLET; POWDER
How can I launch a generic of UPTRAVI before its drug patent expiration?
More Information on Dosage
UPTRAVI family patents
39. Vabomere patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12533342 | REMPEX | NA |
May, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 29, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: 29 August, 2021
Market Authorisation Date: 29 August, 2017
Treatment: Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species...
Dosage: POWDER
More Information on Dosage
VABOMERE family patents
40. Valtoco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12521400 | NEURELIS | NA |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 10, 2023 |
| Orphan Drug Exclusivity(ODE-279) | Jan 10, 2027 |
| New Patient Population(NPP) | Apr 15, 2028 |
Drugs and Companies using DIAZEPAM ingredient
Market Authorisation Date: 10 January, 2020
Treatment: NA
Dosage: SPRAY
How can I launch a generic of VALTOCO before its drug patent expiration?
More Information on Dosage
VALTOCO family patents
41. Vanrafia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12521369 | NOVARTIS | NA |
Feb, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2030 |
Drugs and Companies using ATRASENTAN HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2029
Market Authorisation Date: 02 April, 2025
Treatment: Treatment of primary immunoglobulin a nephropathy (igan)
Dosage: TABLET
More Information on Dosage
VANRAFIA family patents
42. Voxzogo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12514906 | BIOMARIN | Use Of C-Type Natriuretic Peptide Variants To Treat Skeletal Dysplasia |
Aug, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 20, 2026 |
| New Chemical Entity Exclusivity(NCE) | Nov 19, 2026 |
| Orphan Drug Exclusivity(ODE-387) | Nov 19, 2028 |
| Orphan Drug Exclusivity(ODE-449) | Oct 20, 2030 |
Drugs and Companies using VOSORITIDE ingredient
NCE-1 date: 19 November, 2025
Market Authorisation Date: 19 November, 2021
Treatment: Use to increase linear growth in pediatric patients with achondroplasia with open epiphyses
Dosage: POWDER
How can I launch a generic of VOXZOGO before its drug patent expiration?
More Information on Dosage
VOXZOGO family patents
43. Vraylar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943621 | ABBVIE | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(2 years from now) | |
| US7737142 | ABBVIE | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47350 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| USRE49110 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 17, 2020 |
| M(M-213) | Nov 09, 2020 |
| New Indication(I-798) | May 24, 2022 |
| New Indication(I-904) | Dec 16, 2025 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
NCE-1 date: 18 September, 2019
Market Authorisation Date: 18 December, 2025
Treatment: Treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazin...
Dosage: CAPSULE
How can I launch a generic of VRAYLAR before its drug patent expiration?
More Information on Dosage
VRAYLAR family patents
44. Vybrique patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11123287 | IBSA | Orodispersible Films Having Quick Dissolution Times For Therapeutic And Food Use |
Dec, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 16, 2028 |
Drugs and Companies using SILDENAFIL CITRATE ingredient
Market Authorisation Date: 16 December, 2025
Treatment: NA
Dosage: FILM
More Information on Dosage
VYBRIQUE family patents
45. Vyxeos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7850990 (Pediatric) | JAZZ | Compositions For Delivery Of Drug Combinations |
Jul, 2027
(1 year, 4 months from now) | |
|
US9271931 (Pediatric) | JAZZ | Compositions For Delivery Of Drug Combinations |
Jul, 2027
(1 year, 4 months from now) | |
|
US8022279 (Pediatric) | JAZZ | Liposomal Formulations Of Anthracycline Agents And Cytidine Analogs |
Mar, 2028
(2 years from now) | |
|
US8092828 (Pediatric) | JAZZ | Fixed Drug Ratios For Treatment Of Hematopoietic Cancers And Proliferative Disorders |
Oct, 2029
(3 years from now) | |
|
US10028912 (Pediatric) | JAZZ | Method Of Lyophilizing Liposomes |
Apr, 2033
(7 years from now) | |
|
US10166184 (Pediatric) | JAZZ | Method Of Lyophilizing Liposomes |
Apr, 2033
(7 years from now) | |
|
US10835492 (Pediatric) | JAZZ | Method Of Lyophilizing Liposomes |
Apr, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 03, 2020 |
| New Patient Population(NPP) | Mar 30, 2024 |
| Orphan Drug Exclusivity(ODE-287) | Aug 03, 2024 |
| Orphan Drug Exclusivity(ODE-350) | Mar 30, 2028 |
| Pediatric Exclusivity(PED) | Sep 30, 2028 |
Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: POWDER
More Information on Dosage
VYXEOS family patents
46. Wegovy patent expiration
WEGOVY's oppositions filed in EPO
WEGOVY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO NORDISK | Acylated GLP-1 compounds |
Mar, 2026
(19 days from now) | |
| US8129343 | NOVO NORDISK | Acylated GLP-1 compounds |
Dec, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11382957 | NOVO NORDISK | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(5 years from now) | |
| US9278123 | NOVO NORDISK | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(5 years from now) | |
| US10278923 | NOVO NORDISK | Oral dosing of GLP-1 compounds |
May, 2034
(8 years from now) | |
| US12239739 | NOVO NORDISK | Oral dosing of GLP-1 compounds |
May, 2034
(8 years from now) | |
| US11833248 | NOVO NORDISK | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Feb, 2039
(12 years from now) | |
| US12396953 | NOVO NORDISK | Solid Compositions Comprising A Glp-1 Agonist And A Salt Of N-(8-(2-Hydroxybenzoyl)Amino)Caprylic Acid |
Feb, 2039
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Jun 04, 2024 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
| New Indication(I-973) | Aug 15, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
Market Authorisation Date: 22 December, 2025
Treatment: Method of weight reduction and maintenance of weight reduction via oral administration; Method of weight reduction via oral administration; Method of weight reduction
Dosage: TABLET
How can I launch a generic of WEGOVY before its drug patent expiration?
More Information on Dosage
WEGOVY family patents
47. Xphozah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12539299 | ARDELYX | NA |
Nov, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 17 October, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
XPHOZAH family patents